Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- ImmunityBio, Inc.ImmunityBio Reports Phase 3 Data Showing 84% Cystectomy Avoidance at Three Years and Complete Responses Beyond 53 Months with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC With CIS, With or Without Papillary TumorsPeer-reviewed publication reports long-term outcomes from the QUILT-3.032 study supporting durable disease control and bladder preservation CULVER CITY, Calif., October 16, 2026--ImmunityBio, Inc. ( NASDAQ: IBRX ), a commercial-stage immunotherapy company, today announced the publication of long-term d
- Eisai Deepens Its Oncology Evidence Base at ESMO Congress 2026Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today the presentation of clinical research across its oncology portfolio and pipeline during the European Society for Medical Oncology (ESMO) Congress 2026, taking place in Madrid from October 23 to
- Cotecna Group Acquires Energon Labs, Strengthening Global Pharmaceutical Testing Capabilities and Expanding its Presence in IndiaCotecna, a leading provider of Testing, Inspection and Certification (TIC) services, today announced the acquisition of Energon Labs, a cGMP-compliant, USFDA-inspected, ISO 9001:2015 and ISO 17025:2017 certified analytical testing laboratory based in Hyderabad, India.
- Cotecna Group Acquires Energon Labs, Strengthening Global Pharmaceutical Testing Capabilities and Expanding its Presence in IndiaGENEVA, Switzerland and HYDERABAD, India, Oct 16, 2026 - Cotecna, a leading provider of Testing, Inspection and Certification (TIC) services, today announced the acquisition of Energon Labs, a cGMP-compliant, USFDA-inspected, ISO 9001:2015 and ISO 17025:2017 certified analytical testing laboratory based in Hyderabad, India. The acquisition strengthens Cotecna's global Life Sciences platform and expands its pharmaceutical testing capabilities across the Pharmaceutical, Biopharmaceutical, Medical Device and Packaging sectors. Serving customers across India, the United States, Asia-Pacific, and the Middle East, Energon is recognized for its scientific excellence, regulatory expertise and commitment to quality. Strategically located in Hyderabad, one of the world's leading pharmaceutical and biotechnology hubs, Energon provides Cotecna with access to highly specialized scientific talent, advanced laboratory infrastructure and a well-established pharmaceutical ecosystem. India is also one of the world's fastest-growing pharmaceutical markets and a critical manufacturing hub for global healthcare supply chains. The acquisition enhances the Cotecna's ability to support both Indian and international customers with high-quality, regulatory-compliant testing services while delivering greater responsiveness, scalability and operational efficiency across key markets. The addition of Energon further complements Cotecna's growing pharmaceutical testing network which includes Cotecna Life Sciences, Shiva Analyticals and Neotron Pharma. Together, this capabilities strengthen the Group's ability to support customers throughout the product lifecycle and address evolving global quality, compliance and regulatory requirements. Energon offers a comprehensive portfolio of analytical testing and quality assurance services, including analytical method development and validation, stability studies, impurity profiling, extractables and leachables, glass delamination studies, peptides and oligonucleotide characterisation, raw material and finished product testing, in-vitro binding studies, packaging compatibility studies, and regulatory support services. These capabilities will further strengthen Cotecna's position as a trusted partner to pharmaceutical manufacturers serving regulated markets worldwide. Sébastien Dannaud, Chief Executive Officer of Cotecna Group, commented: “We are pleased to welcome Energon Labs to the Cotecna Group. This acquisition represents another important step to support our ambition to become one of the largest providers of Life Sciences testing services in India,and strengthens our position in one of the world's most important pharmaceutical markets.” Amit Chopra, CEO South Asia and Middle East, Cotecna Group, added: "I am delighted to welcome Manikanth Reddy and the talented team of Energon Labs to the Cotecna group. This acquisition aligns perfectly with our strategy of building a comprehensive pharmaceutical testing ecosystem across key growth markets. Energon's strong technical capabilities, experienced team and established customer relationships will enhance our ability to serve pharmaceutical, biopharmaceutical and medical device companies across India and globally. Together, we are creating a stronger platform to support the evolving needs of the pharmaceutical and healthcare sectors. " Manikanth Reddy, Founder, Energon, said: "Joining the Cotecna Group opens an exciting new chapter for Energon Labs. Over the years, we have focused on building a laboratory recognized for quality, scientific expertise and reliability. Becoming part of a global organization like Cotecna provides new opportunities to expand our capabilities, strengthen our service offerings and deliver even greater value to our customers. Our team remains committed to maintaining the highest standards of analytical excellence while supporting the continued growth of the life sciences industry.” About Energon Labs Energon Labs is a cGMP-compliant, USFDA-inspected, ISO 9001:2015 and ISO 17025:2017 certified analytical testing laboratory located in Hyderabad, India. The company provides comprehensive analytical testing, quality assurance and regulatory support services to pharmaceutical, biopharmaceutical, medical device and packaging industries, serving customers across India, the United States, Asia Pacific and the Middle East. About Cotecna Founded in Switzerland in 1974, Cotecna is a leading provider of Testing, Inspection and Certification services. With operations in more than 55 countries, Cotecna helps clients ensure quality, safety, compliance and sustainability across global supply chains. The Group serves customers across agriculture and food, pharmaceuticals, minerals and metals, consumer products, certification and ESG services through a worldwide network of experts, laboratories and technical specialists.
- AI in Drug Discovery Market Size to Worth USD 17.56 Billion by 2031, at a CAGR of 28.1% – MarketsandMarkets™MarketsandMarkets™ projects the global AI in drug discovery market to grow from USD 5.09 billion in 2026 to USD 17.56 billion by 2031, at a CAGR of 28.1% during the forecast period. Market growth is driven by the growing pharmaceutical demand to reduce drug discovery timelines and R&D costs, increasing adoption of generative AI and foundation models, expanding availability of multi-omics datasets, and investments in AI-enabled drug discovery platforms. Increasing strategic collaborations between pharmaceutical companies and AI technology providers, coupled with advances in cloud computing, high-performance computing, and computational biology, are further boosting the adoption of AI across early-stage drug discovery.
- Why Virtual Asset Providers Are Financial Crime Investigation’s Most Underused AllyBy Japhet Gana, Group Head, Transaction Risk & Financial Crimes, Yellow Card I recently spent five days in Nairobi watching investigators, regulators, and virtual asset providers work through the same simulated scenarios in the same room, at a training run by the United Nations Office on Drugs and Crime. I walked in expecting a […]
- Global Frankincense Extract Market Size, Growth, Share and Outlook 2026–2034The global Frankincense Extract Market is gaining momentum as consumers increasingly seek natural ingredients for personal care, wellness, aromatherapy, and pharmaceutical applications. Frankincense extract, derived from the resin of Boswellia trees, has a long history of use in traditional wellness ... Read more
- Shenzhen Chipscreen Biosciences Co., Ltd.Chipscreen Biosciences Announces NMPA IND Approval for NW001, a PD-L1-Targeted Epigenetic Immune-Modulating Antibody ConjugateSHENZHEN, China, October 16, 2026--Shenzhen Chipscreen Biosciences Co., Ltd. ("Chipscreen Biosciences") (SSE: 688321) today announced that NW001, a first-in-class epigenetic immune-modulating antibody conjugate (EIMAC) co-developed with Chengdu Chipscreen Newway Biosciences Co., Ltd., has obtained IND
- Moleculin Announces Reverse Stock SplitMoleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that it filed an amendment to its amended and restated certificate of incorporation with the Secretary of State of the State of Delaware to effect a 1-for-20 reverse stock split of its common stock. The reverse stock split will take effect at 12:01 am (Eastern Time) on October 20, 2026, and the Company’s common stock will open for trading on The Nasdaq Capital Market on October 20, 2026 on a post-split basis, under the existing ticker symbol “MBRX” but with a new CUSIP number 60855D 507.
- SafeSpace Global Extends Exclusive BMRT Security Agreement to Houses of Worship and Addiction Treatment CentersBMRT’s Base Molecular Resonance™ Technology Detects the Molecular Signature of a Concealed Firearm from More Than 500 Feet Away and Identifies Drugs Inside Vehicles and Backpacks at a Distance; Expansion Adds More Than 374,000 U.S. Congregations and Treatment Facilities to SafeSpace Global’s Addressable Market
- Animal Drug Compounding Market Outlook Highlights Rising Veterinary DemandThe right medication is not always available in the right strength, dosage form, or flavor for every animal. A dog may struggle with tablets, a [read full press release...]
- PharmaEssentia CorporationFrom Taiwan to the World: PharmaEssentia Expands Global Reach With New Drug Approvals, Overseas InvestmentsFrom Taiwan to the world: PharmaEssentia expands global reach with new drug approvals, overseas investments TAIPEI, Taiwan, October 16, 2026--PharmaEssentia Corporation (TWSE: 6446), a Taiwan-based biopharmaceutical company, is expanding its global presence through new drug approvals, clinical trials a